Selected Publications

• Sasca D, Guezguez B, Kühn MWM. Next generation epigenetic modulators to target myeloid neoplasms. Curr Opin Hematol. 2021 Sep 1;28(5):356-363.

•  Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, Taubert MC, McGeehan GM, Chen C, Mupo A, Hähnel PS, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, and Kühn MWM  Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. Blood 2020, 136(21):2442-2456  

• Kühn MWM, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Rahnamay Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, McGeehan G, Vassiliou GS, Hoshii T, and Armstrong SA. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov. 2016;6(10):1166-81.  
   
• Kühn MWM and Armstrong SA. Designed to kill: Novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 2015;27(4):431-3. Preview Article
   
• Kühn MWM*, Hadler MJ*, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM, Armstrong SA. MLL-PTD leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 2015;100(5):e190-3. *equal contribution
   
• Kühn MWM, Bullinger L, Gröschel S, Krönke J, Edelmann J, Rücker FG, Eiwen K, Paschka P, Gaidzik VG, Holzmann K, Schlenk RF, Döhner H, Döhner K. Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. Haematologica. 2014;99(8):e133-5.
   
• Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MWM, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia. Blood. 2013;122(1):100-8.
   
• Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MWM, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IGH, Berna Beverloo H, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Krauter J, Ganser A, Valk PJM, Löwenberg B, Döhner K, Döhner H*, Delwel R*. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups. J Clin Oncol. 2013;31(1):95-103. 
    
• Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MWM, Paschka P, Kayser, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, and Bullinger L. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin-remodeling and splicing. Blood. 2012;120(18):e83-92.
   
• Kühn MWM*, Radtke I*, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H*, Downing JR*. High resolution genomic profiling of adult and pediatric Core-Binding Factor Acute Myeloid Leukemia reveals new recurrent alterations. Blood. 2012;119(10):e67-75. *equal contribution
   
• Hummel M, Bentik S, Berger H, Klapper W, Wessendorf S, Barth TFE, Bernd HW, Cogliatti, SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Kühn M, Lenze D, Lichter P, Ignacio MS, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szcepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Stein H, Siebert R. A biologic definition of Burkitt’s Lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-30.